Global Bioprocess Technology Market - 2023-2030

Global Bioprocess Technology Market - 2023-2030

Global Bioprocess Technology Market reached US$ XX billion in 2022 and is expected to reach US$ XX million by 2030 growing at a CAGR of XX% during the forecast period 2023-2030.

Bioprocess technology is the industrial application of biological processes involving living cells or their components to effect the desired transformation of substrates. The major advantages of bioprocesses over traditional chemical processes are that they require mild reaction conditions, are more specific and efficient, and produce renewable by-products (biomass). The development of recombinant DNA technology has expanded and extended the potential of bioprocesses.

Bioprocessing or biotechnology is used in the production of pharmaceuticals, foods, flavours, fuels and chemicals with the aid of a biocatalyst such as an enzyme, microorganisms, plant cell, or animal cell in a bioreactor. It also involves genetic engineering for the manipulation of plants, animals, and microorganisms such as yeasts, bacteria and fungi.

Market Dynamics: Drivers and Restraints

Rise in investments in research and development by biotechnology and pharmaceutical companies

The rise in investments in research and development by biotechnology and pharmaceutical companies is one of the key factors that helps the market to grow during the forecast period. Because of the transition of pharmaceutical firms towards biotechnology, which has created development potential, the biopharmaceutical industry has strengthened its roots across the medical and pharmaceutical industries.

For instance, an article published in the Biotechnology Report in July 2022 stated that growing technological developments in biopharmaceutical and pharmaceutical sectors like 3D bioprinting, biosensors, and gene editing, as well as the incorporation of cutting-edge artificial intelligence and virtual and augmented reality, are expected to open growth opportunities by increasing and speeding the production through bioprocessing.

Moreover, in October 2022, Oculis SA and European Biotech Acquisition Corp. reported they had entered into a definitive business combination agreement. This agreement is to accelerate the development of Oculis' differentiated ophthalmology pipeline. This product addresses areas of significant medical need, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indications, such as glaucoma, affecting growing patient populations.

Furthermore, an increase in the funding for research and development of bioprocessing technology is estimated to propel the growth of the global bioprocess market. Continuous technological advancements in the bioprocess Moreover, increasing support from the governments of various countries in terms of biofuel production is further expected to drive the growth of the bioprocess technology market.

Market Dynamics: Restraint

Strict regulations are one of the factors that hamper the market growth during the forecast period. The market players in the bioprocess technology sector find it difficult to advance at the growth pace. Many governments around the world have already taken action, and some of them are choosing to impose severe regulation policies backed by the high cost of the market instruments that are preventing the market from expanding during the projected period. Also, the high cost of technology and lack of skilled professionals are the factors that hamper the market growth during the forecast period.

Segment Analysis

The global bioprocess technology is segmented based on product type, consumables and accessories, application, end-user and region.

The bioreactors from the product type segment accounted for approximately 39.2% of the market share

The bioreactors from the product type segment accounted for approximately 39.2 % and it is expected to be dominated during the forecast period. A bioreactor is an indispensable part of any bioprocess irrespective of whether the process degrades pollutants or produces substances such as foods, feeds, chemicals and pharmaceuticals, and tissues and organs for use in biomedicine.

For instance, in August 2023 Sartorius and Repligen launched an integrated bioreactor system that incorporates Repligen XCell ATF upstream intensification technology into Sartorius’ Biostat STR bioreactor. The goal is to simplify intensified seed train and N perfusion implementation for biopharmaceutical manufacturers, according to both companies.

Moreover, in March 2022 Argentinian biotechnology firm Stämm Biotech has reportedly closed a $17 million Series A funding round which will help the company accelerate the development of its next-generation 3D printed bioreactor. The firm is developing its microfluidics-based bioreactor using its proprietary self-developed Brick Printing Technology which powers its Sclereid 3D printer. According to Stämm, the 3D printer’s capabilities could extend to building the installed capacity of bioreactors worldwide for biopharma in just one year.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the escalating demand for quality biologics and the rising investments in R&D activities by the major players. Moreover, the high prevalence of chronic diseases that mostly use biopharmaceuticals for treatments and the established healthcare infrastructure in the region has significantly contributed to the industry growth.

For instance August 2022 Beckman Coulter Life Sciences announced a partnership with Flownamics to create an automated, online solution for bioprocess culture monitoring and control. This automated integration removes error-prone manual steps while enabling load-and-go sample runs for up to eight bioreactors, GMP compliance with electronic data management, and continuous control of viable cell density, including remote workflows.

COVID-19 Impact Analysis

The COVID-19 pandemic has created unprecedented stress on supply chains in nearly every global manufacturing segment. Bioprocessing and healthcare have been hit especially hard as suppliers struggle to find materials to meet the demand for COVID-19 vaccines and therapeutics. On top of ongoing non-COVID biologics projects being manufactured, this has created serious supply chain stress.

Market Segmentation

By Product Type
• Bioreactors
• Instruments
• Bioprocess Analyzers
• Osmometers
• Incubators
• Others

By Consumables and Accessories
• Culture Media
• Reagents
• Others

By Application
• Recombinant Proteins
• Monoclonal Antibodies
• Antibiotics
• Others

By End-User
• Biopharmaceutical Companies
• Contract Manufacturing Organizations
• Academic Research Institutes
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in bioprocess technology market include Thermo Fisher Scientific Inc., Sartorius, Roche, Repligen, Merck, SolidaBiotech, Univercellstech, Advanced Instruments, ELITechGroup Inc, Cytiva and among others.

Key Developments

 In July 2023 Molecular Devices, LLC., a leading high-performance life science solutions provider, continues industrializing biology with its organoid line expansion services to support next-generation drug discovery. The offering leverages proprietary bioreactor and bioprocess technology to scale up the production of standardized, assay-ready organoids originating from customer-supplied organoid lines or patient-derived xenografts (PDX).

 In October 2022 PharmNXT Biotech unveils its first integrated manufacturing unit for single-use bioprocessing systems. In line with 'Make in India', the Government's flagship program, Mumbai-based PharmNXT Biotech launched its first integrated manufacturing unit in Pune to provide single-use bioprocessing solutions. The facility has been launched to address the challenges of biologics manufacturing in the country.

 In June 2022 Merck, a leading science and technology company, announced that it has entered a collaboration with Agilent Technologies to advance Process Analytical Technologies (PAT). PAT, which is strongly encouraged by global regulatory authorities, is a key enabler for real-time release and Bioprocessing 4.0.

Why Purchase the Report?
• To visualize the global bioprocess technology market segmentation-based product type, consumables and accessories, application, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous bioprocess technology market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global bioprocess technology market report would provide approximately 69 tables, 70 figures, and 185 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies